Previous functional in vitro studies developed by our group showed that siRNA-mediated SPRY4 gene silencing induced a significant decrease in TPC-1 viable cells, suggesting that this gene may have an oncogenic activity in follicular-cell-derived thyroid cancer [45]. The gene discussed is SPRY4; the disease is thyroid cancer.